Marcel Plattner – President, vips, Switzerland
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing…
Tagged with Pricing
Axel B Müller – Managing Director, Intergenerika,…
Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…
Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…
Has the Time Truly Come for Trudeau’s ‘National Pharmacare’…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the…
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
US Elections: Biden & Trump’s Unworkable Drug Pricing…
In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on…
This Could Get Messy: Trump’s New ‘Most Favoured Nation’…
Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…
Italy Takes Global Lead in Pricing Transparency by Forcing Pharma…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the…
Supporting Value-Based Purchasing in the US Through Changes in…
Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price…
Overcoming US Pricing & Reimbursement Challenges
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s…
Chinese Biotechs’ Domestic Pricing Strategies
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly…
Drugmakers Push Back Against Canada’s New Pricing…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their…
